Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Evolve Telemed vs YourHealthRx

Evolve Telemed
Graded #379

Lower grade

vs+11.499999999999993
YourHealthRx
Graded #119

Higher grade

The verdict

YourHealthRx takes it — 69.6/100 to 58.1/100.

YourHealthRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. YourHealthRx is a scientist-founded peptide and GLP-1 telehealth platform available in all 50 states and DC via a multi-state (IMLC) clinician network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueYourHealthRx +8
45
53
Dose & formulationYourHealthRx +22
53
75
Clinical oversightYourHealthRx +4
83
87
Labs & monitoringYourHealthRx +15
52
67
FulfillmentYourHealthRx +32
62
94
Contract termsEvolve Telemed +22
55
33
Evolve Telemed · left barYourHealthRx · right bar

The numbers

MetricEvolve TelemedYourHealthRx
WeighScore58.1/10069.6/100
GradeCC
Scorecard rank#379#119
SemaglutideNot disclosed$170/mo (compounded)
TirzepatideNot disclosed$210/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Evolve Telemed

Graded #379 · C

Strengths

  • Established hormone- and peptide-optimization brand with board-certified specialists and a physician-plus-care-specialist support model
  • Compounded GLP-1 (semaglutide) weight care offered alongside TRT, menopause/BHRT, thyroid and sexual-wellness programs in one practice
  • Coordinated couples care plans plus dedicated men's and women's tracks
  • Free consultation to start, with published press, blog and FAQ resources

Where it loses points

  • No GLP-1 pricing published — cost is only revealed after a consultation, so you can't compare value upfront
  • Doesn't list the states it serves or name its compounding pharmacies
  • Weight loss is one of many verticals, not a dedicated GLP-1-first program
  • Tirzepatide availability isn't confirmed on the site; only compounded semaglutide is referenced
  • Not shown on our price-ranked /best lists because no pricing is disclosed
YourHealthRx

Graded #119 · C

Strengths

  • Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
  • Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
  • Flat subscription price that doesn't change as your dose increases (no titration penalty)
  • Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
  • Transparent, education-first positioning with published medical disclaimer, privacy, and terms

Where it loses points

  • Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
  • Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
  • No LegitScript certification displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard